Trial · NCT03430843
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set | Tislelizumab | 8.6 | 95% Confidence Interval 7.5 to 10.4 | Months | |
| Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set | Investigator Chosen Chemotherapy | 6.3 | 95% Confidence Interval 5.3 to 7.0 | Months | |
| Overall Survival (OS) in the PDL-1 Positive Analysis Set | Tislelizumab | 10.2 | 95% Confidence Interval 8.5 to 14.5 | Months | |
| Overall Survival (OS) in the PDL-1 Positive Analysis Set | Investigator Chosen Chemotherapy | 5.1 | 95% Confidence Interval 3.8 to 8.2 | Months | |
| Objective Response Rate (ORR) in the ITT Analysis Set | Tislelizumab | 20.3 | 95% Confidence Interval 15.6 to 25.8 | Percentage of Participants | |
| Objective Response Rate (ORR) in the ITT Analysis Set | Investigator Chosen Chemotherapy | 9.8 | 95% Confidence Interval 6.4 to 14.1 | Percentage of Participants | |
| Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets | Tislelizumab | 26.3 | 95% Confidence Interval 17 to 37.3 | Percentage of Participants | |
| Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets | Investigator Chosen Chemotherapy | 11.3 | 95% Confidence Interval 4.7 to 21.9 | Percentage of Participants | |
| Progression-free Survival (PFS) in the ITT Analysis Set | Tislelizumab | 1.6 | 95% Confidence Interval 1.4 to 2.7 | Months | |
| Progression-free Survival (PFS) in the ITT Analysis Set | Investigator Chosen Chemotherapy | 2.1 | 95% Confidence Interval 1.5 to 2.7 | Months | |
| Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set | Tislelizumab | 2.7 | 95% Confidence Interval 1.5 to 4.2 | Months | |
| Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set | Investigator Chosen Chemotherapy | 2.3 | 95% Confidence Interval 1.4 to 3.0 | Months | |
| Duration of Response (DOR) in the ITT Analysis Set | Tislelizumab | 7.1 | 95% Confidence Interval 4.1 to 11.3 | Months | |
| Duration of Response (DOR) in the ITT Analysis Set | Investigator Chosen Chemotherapy | 4.0 | 95% Confidence Interval 2.1 to 8.2 | Months | |
| Duration of Response (DOR) in the PDL-1 Positive Analysis Set. | Tislelizumab | 7.1 | 95% Confidence Interval 2.9 to 13.2 | Months | |
| Duration of Response (DOR) in the PDL-1 Positive Analysis Set. | Investigator Chosen Chemotherapy | 5.7 | 95% Confidence Interval 1.2 to NA | Months | |
| Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set | Tislelizumab | Baseline | 16.2 | Standard Deviation 12.28 | Score on a scale |
| Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set | Investigator Chosen Chemotherapy | Baseline | 18.3 | Standard Deviation 13.86 | Score on a scale |
| Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set | Tislelizumab | Change at Cycle 6 | 0.2 | Standard Deviation 8.28 | Score on a scale |
| Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set | Investigator Chosen Chemotherapy | Change at Cycle 6 | 4.8 | Standard Deviation 9.38 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03430843/results